All Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06131372
NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease and type 2 diabetes.
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The purpose of this study is to see whether CagriSema can lower kidney damage. This will be compared to the effects of semaglutide, cagrilintide and placebo.
Study Duration...
-
NCT05845710
Protection against Emboli during caRotid artery stenting using a Neuroguard IEP® Direct 3-in-1 delivery system comprised oF a pOstdilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt III
This study is not currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Orlando, FloridaTo evaluate the safety and effectiveness of direct carotid access for stenting using
the Neuroguard IEP Direct System in subjects at high risk for carotid
endarterectomy who require carotid... -
NCT06081894
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN COMPARED TO PLACEBO IN ADULTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Department #: 407-303-7556
This study is not currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the effects of aficamten and placebo on health status and exercise capacity in participants with nHCM. The safety and tolerability of aficamten at different...
-
NCT06188559
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine if a new drug called BB-1701 is safe and effective in people who have HER2-positive or HER2-low, unresectable or metastatic breast cancer (MBC). There are two...
-
ACCESS-T1D: Accessing Care, Clinical Trials and Screening for Underserved Children and Adults with Type 1 Diabetes
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaACCESS T1D es un estudio patrocinado por AdventHealth y el Departamento de Salud del Estado de Florida que busca personas con riesgo de padecer diabetes tipo 1 (DT1).
El objetivo de este estudio es... -
NCT06313528
TRIPLE G: A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 versus Placebo on Calorie Intake and Energy Expenditure in Participants with Obesity Under Calorie Restriction
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The purposes of this study are to look at the effect of the study drug compared to placebo (a drug that looks like the study drug but has no active medicine) on calorie intake...
-
NCT05901831
FINE-ONE: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of Finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The aim of the study is to demonstrate efficacy of Finerenone when compared to placebo, in addition to standard of care, in delaying the progression of chronic kidney disease (CKD) in...
-
NCT05891171
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchObjectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the...
-
NCT06122961
POSEIDON – Prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease and heart failure
This study is not currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Tampa, FloridaWe are doing this study to collect information about the number of people with cardiovascular disease who have high levels of inflammation throughout the body. Cardiovascular disease is a general name...
-
NCT05904886
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)
This study is not currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this...
-
NCT06253130
EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in...
-
NCT04717414
ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
This study is not currently enrolling.Associated Conditions: LymphomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking...